PRQR — ProQR Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $182.05m
- $68.00m
- €16.35m
ProQR Q2 revenue more than doubles
Brief: ProQR Therapeutics Q2 EPS EUR -0.08
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
Brief: Proqr Prices $50.0 Million Underwritten Registered Direct Offering And Concurrent Private Placement
Brief: Proqr Announces Positive Phase 1 Target Engagement Data For Ax-0810, Establishing First Clinical Validation Of The Axiomer Rna Editing Platform
ProQR Therapeutics Q1 revenue falls and misses estimates
Brief: ProQR Therapeutics Q1 EPS EUR -0.13
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
ProQR rises after AI drug discovery tie-up with Ginkgo Bioworks
Brief: Proqr Announces Partnership With Ginkgo Bioworks And Formation Of Ai Advisory Board
Brief: Proqr Announces Encouraging Ax-0810 Phase 1
ProQR Q3 revenue misses estimates, reports net loss
Brief: ProQR Therapeutics Q3 EPS EUR -0.1
Brief: ProQR Therapeutics NV - Receives CTA Authorization for Phase 1 Study of AX-0810
ProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary
ProQR Q2 revenue and EPS miss estimates
ProQR Therapeutics NV expected to post a loss of 8 cents a share - Earnings Preview